Myriad Genetics Expands Precise MRD Test to Colorectal, Renal, and Breast Cancers, Backed by Strong Clinical Data
MYGN sits 29% above its 52-week low of $3.53.
Summary
Myriad Genetics has expanded the availability of its Precise MRD test to include colorectal, renal, and breast cancers, significantly broadening its market reach. This expansion is supported by the publication of the MONITOR-Breast study, which demonstrated the test's clinical validity, including 100% specificity for predicting pathological complete response in breast cancer. This move targets over 6 million individuals in the U.S. with these cancers and represents a key step in the company's precision oncology strategy, providing robust evidence for guiding treatment and surveillance decisions.
At the time of this announcement, MYGN was trading at $4.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425M. The 52-week trading range was $3.53 to $8.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.